Using Naltrexone for Methamphetamine Addiction

Naltrexone, a medication originally developed to treat opioid and alcohol dependence, has emerged as the most promising pharmacological lead for methamphetamine addiction, but with an important catch: the strongest evidence supports it only when combined with the antidepressant bupropion. A landmark clinical trial published in the New England Journal of Medicine found that the naltrexone-bupropion combination produced significantly more negative drug tests than placebo, marking the first time any medication had cleared that bar for methamphetamine use disorder in a large, rigorous trial. The picture is more complicated than a single headline, though, because naltrexone on its own has a much weaker track record, and even the combination helps only a fraction of the people who take it.

The ADAPT-2 Trial and What It Actually Found

The study that put naltrexone-bupropion on the map is known as ADAPT-2 (Accelerated Development of Additive Pharmacotherapy Treatment). It enrolled hundreds of participants across multiple sites and used a two-stage adaptive design, meaning the trial adjusted enrollment based on early results. Participants received either injectable extended-release naltrexone (380 mg, given as a monthly shot) plus daily oral extended-release bupropion (450 mg) or matched placebos.

The results were statistically clear but modest in absolute terms. In the first stage, about 17% of participants on the active medications tested negative for methamphetamine at three or more consecutive visits, compared with roughly 3% on placebo. In the second stage, the numbers were about 11% versus 2%. Across both stages, the weighted response rate was around 14% for the medication group and about 3% for placebo, an overall treatment effect of about 11 percentage points.¹ That gap was highly statistically significant, but it also means the majority of people on the medication did not meet the study’s definition of “responder.”

That said, the responder definition was strict: three or more consecutive meth-negative urine tests toward the end of the treatment period. A follow-up analysis of the same trial data found that participants who stayed on the active medications for the full 12 weeks showed a continued increase in the probability of testing negative for meth, with a total increase of about 27 percentage points over the treatment period. Those on placebo improved too, but only by about 11 percentage points. The difference between the two groups at 12 weeks was roughly 16 percentage points, suggesting the medication keeps working the longer someone stays on it.²

Why Naltrexone Alone Falls Short

If naltrexone-bupropion works, you might assume naltrexone by itself would do something meaningful. The evidence says otherwise. A placebo-controlled trial specifically testing injectable extended-release naltrexone alone in men who have sex with men found no meaningful difference in meth-positive urine tests between the medication and placebo groups. Urine positivity rates declined in both arms, from about 78% to 70% in the naltrexone group and from about 74% to 64% in the placebo group, a pattern consistent with study participation effects rather than a medication effect.³

A systematic review and meta-analysis that looked across all the pharmacotherapy trials for methamphetamine found that opioid antagonists like naltrexone, when evaluated as a class, produced either low-strength or insufficient evidence of benefit on their own.⁴ The story here is not that naltrexone is useless, but that it seems to need a partner. Bupropion, which boosts dopamine and norepinephrine activity, may be filling in a piece of the puzzle that naltrexone alone cannot address. Methamphetamine addiction involves both the opioid system (where naltrexone acts) and the dopamine system (where bupropion acts), and hitting only one of those targets may not be enough to shift behavior.

How Naltrexone Acts on the Meth-Addicted Brain

Naltrexone is an opioid receptor blocker. It was designed to sit on the same brain receptors that heroin and morphine use, preventing those drugs from producing a high. So why would it do anything about methamphetamine, which works primarily on the dopamine system?

The answer lies in the crosstalk between the opioid and dopamine systems. Methamphetamine floods the brain with dopamine, but the pleasure and reinforcement associated with that flood are partly modulated by the brain’s own opioid signaling. Naltrexone appears to dampen this downstream opioid contribution. A brain imaging study found that naltrexone reduced connectivity in the brain circuits linking the striatum (a key reward area) to the amygdala and limbic system, pathways thought to be critical for drug craving and relapse.⁵

Animal research has added an interesting wrinkle. In rats and mice, naltrexone consistently reduces drug-seeking behavior triggered by environmental cues associated with meth, such as a place where the animal previously received the drug, or lights and sounds that were paired with drug delivery. But naltrexone does not block the reinstatement of drug-seeking triggered by a fresh dose of meth itself.⁶ Rat self-administration studies have confirmed this pattern: naltrexone reduced cue-driven drug-seeking after extinction, but did not alter the dose-response relationship when the animal could directly access meth.⁷

This distinction matters for real life. Much of relapse is driven by cues: walking past a place where you used, seeing paraphernalia, spending time with people associated with use. If naltrexone weakens the grip of those cues without necessarily making meth less rewarding when someone actually uses, it may function primarily as a relapse-prevention tool rather than something that makes the drug unpleasant if taken.

Translational research in primates and humans supports this interpretation. When researchers gave naltrexone to animals that had a long history of amphetamine exposure and then challenged them with a small dose, naltrexone cut the resulting dopamine spike by roughly half. But this effect appeared only after chronic amphetamine exposure, not after a single dose, suggesting naltrexone’s benefit may be specific to the kind of sensitized brain state that develops with long-term stimulant use.⁸

What Naltrexone Does to Craving and the Subjective High

Lab studies in people who use meth have tested what naltrexone does to the experience of the drug in controlled settings. In a double-blind inpatient study, participants received either 50 mg of oral naltrexone or placebo for four days, then were shown meth-related cues and given an intravenous dose of 30 mg of methamphetamine. Naltrexone significantly blunted cue-induced craving and reduced several of the pleasurable subjective effects of the drug, including feelings of stimulation, wanting more of the drug, and craving. It also increased the perception of negative drug effects.⁹

A related analysis found that naltrexone weakened the link between cue-induced craving and the subsequent positive response to meth. In other words, among people on placebo, seeing meth cues predicted stronger enjoyment of the drug when it was administered. Naltrexone disrupted that connection, making the cue-driven craving less predictive of a pleasurable drug experience.¹⁰ This fits with the animal data: naltrexone’s main lever seems to be loosening the learned associations between drug cues and the rewarding effects of meth, rather than blocking the high outright.

One important caveat: a laboratory study that gave participants maintenance doses of naltrexone and bupropion before letting them self-administer intranasal methamphetamine did not find that the combination reduced the reinforcing effects of the drug. Participants still chose to take meth at similar rates regardless of whether they were on the active medications or placebo.¹¹ That study was small and tested acute, controlled administration rather than real-world use, but it reinforces the idea that the medication’s benefit is not about making meth inherently less appealing in the moment. Its value likely accumulates over time, through repeated weakening of cue-reward associations.

Who Responds Best to the Treatment

Not everyone in the ADAPT-2 trial responded equally. A subgroup analysis examined whether sexual orientation affected outcomes, since men who have sex with men (MSM) represent a disproportionately large share of the meth-using population in many urban areas. The analysis found that the treatment effect was significantly larger for MSM compared with men who have sex exclusively with women. Among MSM, response rates on active treatment were roughly 14% in one stage and 23% in the other, compared with about 3-4% on placebo. Among men who have sex exclusively with women, the gap between treatment and placebo was much smaller and did not clearly separate from placebo in the first stage.¹²

The reasons behind this difference are not settled. It could reflect differences in patterns of use (MSM in this trial tended to use meth in the context of sexual behavior, which involves specific cues that naltrexone may be well suited to disrupt), differences in motivation, or other unmeasured factors. The finding does not mean the medication doesn’t work for heterosexual men; it means the evidence is stronger for one group than the other.

Cognitive factors also appear to matter. A separate analysis found that naltrexone’s effects on craving and subjective drug response were strongest among participants who scored lower on tests of executive function, the brain’s capacity for impulse control, planning, and cognitive flexibility. People with higher executive function scores showed less benefit from naltrexone, possibly because they already had enough cognitive control to moderate their responses to drug cues on their own.¹³ This is a useful clinical insight: the people who are most impulsive and most vulnerable to cue-driven relapse may be exactly the ones who get the most from the medication.

Targeted Use for People Who Also Drink

Methamphetamine use frequently co-occurs with heavy drinking, and naltrexone already has FDA approval for alcohol use disorder. A pilot study explored “targeted” naltrexone, where participants took the medication only on days they anticipated using meth or binge drinking rather than every day. Among those who actually took the medication regularly, naltrexone was associated with a roughly 22% reduction in meth-using days and a 28% reduction in binge-drinking days compared with placebo.¹⁴ This was a small feasibility study, not a definitive trial, but it suggests that even an as-needed dosing strategy might help people who have overlapping stimulant and alcohol problems. The practical appeal is obvious: a single medication that addresses two co-occurring issues without requiring a daily commitment.

Real-World Barriers to Access

Even if the evidence for naltrexone-bupropion grows stronger, getting the medication to patients is not straightforward. The injectable form of naltrexone (marketed as Vivitrol) is the version used in the clinical trials, and it comes with significant logistical hurdles. A qualitative study examining barriers to routine use of extended-release naltrexone in clinical settings identified a cluster of problems. The medication requires a specific ordering process, must be kept refrigerated, and needs to be administered by a healthcare provider via intramuscular injection every four weeks. Cost was a major concern: without insurance coverage, a single monthly injection can run over a thousand dollars. Programs also reported that insurance formulary restrictions, prior-authorization requirements, and a broader institutional culture resistant to medication-assisted treatment limited uptake.¹⁵

There is also the challenge that naltrexone-bupropion for methamphetamine is entirely off-label. No regulatory agency has approved any medication specifically for methamphetamine use disorder. Clinicians who prescribe this combination are working from clinical trial data and expert guidance, not an FDA-stamped indication. That makes insurance coverage even harder to secure, since payers are less willing to reimburse off-label prescriptions. For treatment programs that already face skepticism about using any medications for addiction, adding an off-label combination with complex logistics can feel like an uphill battle.

How It Fits Alongside Behavioral Treatment

No one in the field thinks naltrexone-bupropion replaces behavioral interventions. The current standard of care for meth addiction relies heavily on contingency management (providing rewards for clean drug tests) and cognitive behavioral therapy. The ADAPT-2 trial itself included supportive counseling for all participants, including those on placebo. The question is whether the medication adds something on top of what behavioral treatment alone can do.

The ADAPT-2 results suggest that it does, at least for a subset of people. But the absolute response rates are a reminder that pharmacotherapy for meth addiction is in its infancy. For comparison, medications for opioid addiction like methadone and buprenorphine retain the majority of patients in treatment and produce dramatic reductions in illicit use. Nothing close to that exists for methamphetamine yet. The naltrexone-bupropion combination is the best pharmacological option available, but “best available” and “highly effective” are different statements.

For someone considering this treatment, the realistic expectation is that the medication may take the edge off cravings, especially in situations where environmental triggers are strong, and that staying on it for at least 12 weeks gives it the best chance of producing meaningful change. It is not a cure, and it works best as one element in a broader treatment plan that includes counseling, social support, and strategies for avoiding high-risk situations. The people most likely to benefit appear to be those with the hardest time controlling impulses on their own, which is exactly the group that most needs help.

The Role of Craving and Impulsivity in Treatment Response

Researchers working with the ADAPT-2 data have been trying to understand why some participants responded and others did not. One analysis looked specifically at craving and impulsivity as predictors. The trial confirmed that naltrexone-bupropion reduced craving, and that reductions in craving were associated with lower subsequent methamphetamine use.¹⁶ This makes intuitive sense: if the medication dampens the urge to use, people use less. But the size of the craving reduction varied widely across individuals, and the field still lacks a reliable way to predict in advance who will experience the strongest anti-craving effect.

The impulsivity findings from the executive function study mentioned earlier add another dimension. Meth itself damages prefrontal brain regions involved in self-control, and people who use meth chronically often arrive at treatment with already-diminished impulse regulation. The evidence so far suggests that naltrexone may partially compensate for that deficit by quieting the cue-driven reward signals that an impaired prefrontal cortex can no longer override on its own. If that model is correct, naltrexone is not just reducing craving generically, but doing so in a way that is especially helpful for people whose brains have been most affected by chronic meth use. Future trials may eventually use cognitive testing or brain imaging at baseline to identify the patients most likely to benefit, but that kind of precision prescribing is still years away.